Pharmaceutical industry marketing: Understanding its impact on women's health

Obstetrical and Gynecological Survey

Volumn 63, Issue 9, 2008, Pages 585-596

  Sufrin, Carolyn B ^a   Ross, Joseph S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOOXYGENASE 2 INHIBITOR; FLUOXETINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PAROXETINE;

ADJUSTMENT DISORDER; ADVERTIZING; CLINICAL TRIAL; CONFLICT OF INTEREST; CONSUMER; CONTINUING EDUCATION; DEVICE; DRUG INDUSTRY; DRUG MARKETING; EVIDENCE BASED MEDICINE; HEALTH CARE; HERPES SIMPLEX; HUMAN; HYPERTENSION; MAJOR DEPRESSION; MEDICAL EDUCATION; PAPANICOLAOU TEST; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREMENSTRUAL DYSPHORIC DISORDER; REVIEW; WOMEN'S HEALTH; ECONOMICS; FEMALE; METHODOLOGY;

ADVERTISING AS TOPIC; DRUG INDUSTRY; FEMALE; HUMANS; WOMEN'S HEALTH;

EID: 59649125675     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e31817f1585     Document Type: Review

References (108)

1. Fortune Magazine Most Profitable Industries 2006. Available at: http://money.cnn.com/magazines/fortune/fortune500/2007/performers/industries/ return-on-revenues/index.html. Accessed January 18, 2008.
2. Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2007. Washington, DC: PhRMA, 2007.
3. National Association of Chain Drug Stores, Facts and Figures. Available at: http://www.nacds.org/wmspage.cfm? parm 1=6. Accessed January 18, 2008.
4. Intelligence 360. Global Pharmaceutical Perspectives 2006. Norwalk, CT: IMS Health Incorporated, 2006.
5. Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008;3:e1.
6. Pfizer Inc. 2006 Financial Report. 2006. Available at: http://www. pfizer.com/files/annualreport/2006/financial/financial2006.pdf Accessed January 18, 2008.
7. Merck 2006 Annual Review. 2006. Available at: http://www. merck.com/finance/annualreport/ar2006/fivePatients.html. Accessed January 18, 2008.
8. Annual Report 2006, Bristol-Meyers-Squibb. 2006. Available at: http://media.corporate-ir.net/media-files/irol/10/106664/reports/bmy06arlow.pdf. Accessed January 18, 2008.
9. Donohue JM, Cevasco M, Rosenthal MB. A decade of direetto-consumer advertising of prescription drugs. N Engl J Med 2007;357:673-681.
10. Frosch DL, Krueger PM, Hornik RC, et al. Creating demand for prescription drugs: a content analysis of television directto-consumer advertising. Ann Fam Med 2007;5:6-13.
11. Gellad ZF, Lyles KW. Direct-to-consumer advertising of pharmaceuticals. Am J Med 2007;120:475-480.
12. Guidance for Industry: Consumer Directed Broadcast Advertisements. Available at: http://www.fda.gov/cder/Guidance/1804fnl.pdf. 1999.
13. Gahart MT, Duhamel LM, Dievler A, et al. Examining the FDA's oversight of direct-to-consumer advertising. Health Aff (Millwood) 2003;(Suppl Web Exclusives):W3-120-W3123.
14. Kelly P. DTC advertising's benefits far outweigh its imperfections. Health Aff (Millwood) 2004;(Suppl Web Exclusives): W4-246-W4-248.
15. Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. N Engl J Med 2005;352:325-328.
16. Agovino T. Pi-by-no drugs could have saved US $20 billion. The Washington Post 2005 October 25.
17. Wolfe SM. Direct-to-consumer advertising-education or emotion promotion? N Engl J Med 2002;346:524-526.
18. Robinson AR, Hohmann KB, Rifkin JI, et al. Direct-toconsumer pharmaceutical advertising: physician and public opinion and potential effects on the physician-patient relationship. Arch Intern Med 2004;164:427-432.
19. Weissman JS, Blumenthal D, Silk AJ, et al. Physicians report on patient encounters involving direct-to-consumer advertising. Health Aff (Millwood) 2004;(Suppl Web Exclusives): W4-219-W4-233.
20. Aikin K, Swasy J, Braman A. Patient and Physician Attitudes and Behaviors Associated with Direct to Consumer Promotion of Prescription Drugs: Summary of FDA Survey Research Results. Washington, DC: US Department of Health and Human Services, Center for Drug Evaluation and Research, 2004.
21. Huang AJ. MSJAMA. The rise of direct-to-consumer advertising of prescription drugs in the United States. JAMA 2000; 284:2240.
22. Parker RS, Pettijohn CE. Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians. Health Mark Q 2005;22:27-43.
23. Lipsky MS, Taylor CA. The opinions and experiences of family physicians regarding direct-to-consumer advertising. J Fam Pract 1997;45:495-499.
24. Murray E, Lo B, Pollack L, et al. Direct-to-consumer advertising: physicians' views of its effects on quality of care and the doctor-patient relationship. J Am Board Fam Pract 2003; 16:513-524.
25. Donohue JM, Berndt ER, Rosenthal M, et al. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 2004;42:1176-1185. (Pubitemid 39627294)
26. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005;293: 1995-2002.
27. Spence MM, Teleki SS, Cheetham TC, et al. Direct-toconsumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005;62: 544-559.
28. Mintzes B, Barer ML, Kravitz RL, et al. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 2002;324:278-279. (Pubitemid 34121841)
29. Bradford WD, Kleit AN, Nietert PJ, et al. How direct-toconsumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. Health Aff (Millwood) 2006;25:1371-1377.
30. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997; 89:615-622. (Pubitemid 27133540)
31. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception 2006;73:23-29. (Pubitemid 41811184)
32. Ortho Tri-cyclen website, 2008. Avalable at: http://www.orthotricyclen. com/. Accessed April 1, 2008.
33. Barnes JE. A New Age in Acne Treatment: It's No Longer Just a Market for Teenagers. The New York Times 2001 April 27.
34. Cavallucci S. The Top 200: what's making waves in prescription sales. Pharmacy Practice 2006;22:44-47.
35. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-1709. (Pubitemid 39383201)
36. Krumholz HM, Ross JS, Presler AH, et al. What have we learnt from Vioxx? BMJ 2007;334:120-123.
37. PhRMA. Guiding Principles: Direct to Consumer Advertisements about Prescription Medicines. Washington, DC: Pharmaceutical Research and Manufacturers of America, 2005.
38. Tiefer L. Female sexual dysfunction: a case study of disease mongering and activist resistance. PLoS Med 2006;3:e178. DOI:10.1371/journal.pmed.0030178.
39. Payer L. Disease-Mongers: How Doctors, Drug Companies, and Insurers are Making You Feel Sick. New York: Wiley & Sons, 1992.
40. Applbaum K. Pharmaceutical marketing and the invention of the medical consumer. PLoS Med 2006;3:e189. DOI: 10.1371/journal.pmed.0030189.
41. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002;324: 886-891.
42. Moynihan R, Henry D. The fight against disease mongering: generating knowledge for action. PLoS Med 2006;3:e191.
43. Vendantam S. Renamed Prozac Fuels Women's Health Debate. The Washington Post 2001 April 29.
44. 10-K: WARNER CHILCOTT LTD. 2008. Available at: http://www.marketwatch. com/news/story/10-k-warner-chilcott-ltd/story.aspx?guid = %7B40E3852E-1AD3-407F- 853C-713518AF8918%7D. Accessed February 15.
45. McFadden DW, Calvario E, Graves C. The devil is in the details: the pharmaceutical industry's use of gifts to physicians as marketing strategy. J Surg Res 2007;140:1-5. (Pubitemid 46669541)
46. Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? A randomized trial. Am J Med 2005; 118:881-884.
47. Boltri JM, Gordon ER, Vogel RL. Effect of antihypertensive samples on physician prescribing patterns. Fam Med 2002; 34:729-731.
48. Cutrona SL, Woolhandler S, Lasser KE, et al. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Public Health 2008;98:284-289.
49. Greene JA. Attention to 'details': etiquette and the pharmaceutical salesman in postwar American. Soc Stud Sci 2004; 34:271-292.
50. Wall LL, Brown D. The high cost of free lunch. Obstet Gynecol 2007;110:169-173.
51. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-380.
52. Sigworth SK, Nettleman MD, Cohen GM. Pharmaceutical branding of resident physicians. JAMA 2001 ;286:1024-1025.
53. Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med 2007;356: 1742-1750.
54. Levy R. The role and value of pharmaceutical marketing. Arch Fam Med 1994;3:327-332.
55. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995;273:1296-1298.
56. Angell M. The pharmaceutical industry - to whom is it accountable? N Engl J Med 2000;342:1902-1904.
57. Gibbons RV, Landry FJ, Blouch DL, et al. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998;13:151-154.
58. Eaton L. Readers want transparency in link between doctors and drug firms. BMJ 2003;326:1352.
59. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001;110: 551-557.
60. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Arch Intern Med 2003;163:2213-2218. (Pubitemid 37248786)
61. Morgan MA, Dana J, Loewenstein G, et al. Interactions of doctors with the pharmaceutical industry. J Med Ethics 2006;32:559-563.
62. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth 2003;3:39-46.
63. Mauss M. The Gift: the Form and Reason for Exchange in Archaic Societies. London: WW Norton, 1990.
64. Brody H. Pens and other pharmaceutical industry gifts. Am J Bioeth 2003;3:58-60.
65. Brett AS. Cheap trinkets, effective marketing: small gifts from drug companies to physicians. Am J Bioeth 2003;3:52-54.
66. Paris JJ. Large or small, a gift is a gift is a gift. Am J Bioeth 2003;3:W30.
67. Schwartz TL, Kuhles DJ II, Wade M, Masand PS. Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits. Ann Clin Psychiatry 2001;13:159-162. (Pubitemid 34020151)
68. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271:684-689.
69. Saint M, Gildengorin G, Sawaya GF. Current cervical neoplasia screening practices of obstetrician/gynecologists in the US. Am J Obstet Gynecol 2005;192:414-421. (Pubitemid 40214973)
70. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007;335:28.
71. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167-177.
72. Sawaya GF. Evidence-based medicine versus liquid-based cytology. Obstet Gynecol 2008;111:2-3.
73. Steinbrook R. Financial support of continuing medical education. JAMA 2008;299:1060-1062. (Pubitemid 351347064)
74. Steinbrook R. Commercial support and continuing medical education. N Engl J Med 2005;352:534-535. (Pubitemid 40204665)
75. Medical Education Services Suppliers: A Threat to Physician Education. Health Research Group Publications, 2000. Available at: http://www.citizen.org/ publications/release. cfm?ID=7142. Accessed April 4, 2008.
76. Steinman MA, Harper GM, Chren MM, et al. Characteristics and impact of drug detailing for gabapentin. PLoS Med 2007;4:e134.
77. US Senate Committee on Finance. Committee Staff Report to the Chairman and Ranking Member: Use of Educational Grants by Pharmaceutical Manufacturers. Washington, DC: Government Printing Office, 2007.
78. Carlat D. Dr. Drug Rep. The New York Times 2007 November 25.
79. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992;102:270-273.
80. Management of Herpes in Pregnancy. ACOG Practice Bulletin No. 82. American College of Obstetricians and Gynecologists. Obstet Gyonecol 2007;109:1233-1248.
81. Brown ZA, Gardella C, Wald A, et al. Genital herpes complicating pregnancy. Obstet Gynecol 2005;106:845-856.
82. Gardella C, Brown Z, Wald A, et al. Risk factors for herpes simplex virus transmission to pregnant women: a couples study. Am J Obstet Gynecol 2005;193:1891-1899.
83. Urato AC, Caughey AB. Universal herpes screening in pregnancy: not recommended and potentially harmful to patients. Am J Obstet Gynecol 2007;196:e15; author reply e-6.
84. Armstrong D. Drug firm's cash sways debate over test. The Wall Street Journal 2006 December 13.
85. GlaxoSmithKline Annual Report 2007. 2007. Available at: http://www.gsk.com/investors/reps07/annual-report-2007. pdf. Accessed January 18, 2008.
86. Moffatt B, Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten journal articles. Perspect Biol Med 2007;50:18-31.
87. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-1170.
88. Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant proindustry findings in medical and surgical randomized trials. CMAJ 2004;170:477-480. (Pubitemid 38293642)
89. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/ Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-1534.
90. Ross JS. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800-1812.
91. Smith R. Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005;2:e138.
92. Flanagin A, Carey LA, Fontanarosa PB, et al. Prevalence of articles with honorary authors and ghost authors in peerreviewed medical journals. JAMA 1998;280:222-224.
93. Guidance for Industry and FDA: Regulation of Medical Devices. 1999. Available at: http://www.fda.gov/cdrh/manual/ireas.html. Accessed March 14, 2008.
94. Center for devices and radiologic health: Premarket notification. 2006. Available at: http://www.fda.gov/cdrh/devadvice/314.html. Accessed March 18, 2006.
95. Ostergard DR. Lessons from the past: directions for the future. Do new marketed surgical procedures and grafts produce ethical, personal liability, and legal concerns for physicians? Int Urogynecol J Pelvic Floor Dysfunct 2007;18: 591-598.
96. McElhatten J. Probe reveals doctor payoffs. The Washington Times 2008 March 18.
97. American Medical Association. Gifts to physicians from industry. In: Code of Medical Ethics of the American Medical Association: Current Opinions with Annotations. Chicago: AMA, 2006-2007:212-216.
98. Relationships with industry. ACOG Committee Opinion No. 401. Obstet Gynecol 2008;111:799-804.
99. PhRMA. Code on Interactions with Healthcare Professionals. Washington, DC: Pharmaceutical Research and Manufacturers of America, 2002.
100. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006;295:429-433. (Pubitemid 43144979)
101. Carrejo A. Testimony to the Special Committee on Aging United States Senate; 2008 March 12.
102. Karnowski S. Minnesota health system purges drug trinkets. The Associated Press 2008 January 19.
103. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4-8. (Pubitemid 12048270)
104. Special Committee on Aging. Kohl Hearing Seeks Alternative to Drug Industry's Controversial Practice of Educating Doctors about New Drugs. Special Committee on Aging, 2008.
105. Accreditation Council for Continuing Medical Education. ACCM E Standards for Commercial Support. Chicago: Accreditation Council for Continuing Medical Education, 2007.
106. Ross JS, Lackner JE, Lurie P, et al. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA 2007;297:1216-1223. (Pubitemid 46469916)
107. Alina Baciu, Stratton K, Burke SP, eds. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: Institute of Medicine, 2007.
108. Schneider JA, Arora V, Kasza K, et al. Residents' perceptions over time of pharmaceutical industry interactions and gifts and the effect of an educational intervention. Acad Med 2006;81:595-602.